JP4733047B2 - ロスバスタチンの特性評価のためのリファレンス・スタンダード - Google Patents
ロスバスタチンの特性評価のためのリファレンス・スタンダード Download PDFInfo
- Publication number
- JP4733047B2 JP4733047B2 JP2006541502A JP2006541502A JP4733047B2 JP 4733047 B2 JP4733047 B2 JP 4733047B2 JP 2006541502 A JP2006541502 A JP 2006541502A JP 2006541502 A JP2006541502 A JP 2006541502A JP 4733047 B2 JP4733047 B2 JP 4733047B2
- Authority
- JP
- Japan
- Prior art keywords
- rosuvastatin
- degradation product
- lactone
- product
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52644903P | 2003-12-02 | 2003-12-02 | |
US60/526,449 | 2003-12-02 | ||
PCT/US2004/040329 WO2005056534A1 (en) | 2003-12-02 | 2004-12-02 | Reference standard for characterization of rosuvastatin |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007512354A JP2007512354A (ja) | 2007-05-17 |
JP2007512354A5 JP2007512354A5 (US07692009-20100406-C00002.png) | 2009-10-08 |
JP4733047B2 true JP4733047B2 (ja) | 2011-07-27 |
Family
ID=34676616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006541502A Expired - Fee Related JP4733047B2 (ja) | 2003-12-02 | 2004-12-02 | ロスバスタチンの特性評価のためのリファレンス・スタンダード |
Country Status (13)
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
WO2005056534A1 (en) * | 2003-12-02 | 2005-06-23 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
US7851624B2 (en) | 2003-12-24 | 2010-12-14 | Teva Pharamaceutical Industries Ltd. | Triol form of rosuvastatin and synthesis of rosuvastatin |
CA2591439C (en) | 2005-02-22 | 2013-03-26 | Teva Pharmaceutical Industries Ltd. | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof |
AU2006329006B2 (en) * | 2005-12-20 | 2013-02-28 | Lek Pharmaceuticals D.D. | Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid |
EP2121631A2 (en) * | 2007-03-13 | 2009-11-25 | Teva Pharmaceutical Industries Ltd. | Triol form of rosuvastatin |
EP2189456A1 (en) * | 2008-11-14 | 2010-05-26 | LEK Pharmaceuticals d.d. | New compounds prepared from omeprazole |
JP5739820B2 (ja) | 2008-12-30 | 2015-06-24 | アークル インコーポレイテッド | 置換5,6−ジヒドロ−6−フェニルベンゾ[f]イソキノリン−2−アミン化合物 |
CN103454352B (zh) * | 2013-07-30 | 2015-07-15 | 广东先强药业有限公司 | 一种hplc法测定瑞舒伐他汀钙的含量及其有关物质的方法 |
CN103776939A (zh) * | 2014-02-11 | 2014-05-07 | 润泽制药(苏州)有限公司 | 瑞舒伐他汀钙制剂有关物质的制备检测方法 |
CN108398501A (zh) * | 2018-03-02 | 2018-08-14 | 海南通用三洋药业有限公司 | 一种检测瑞舒伐他汀钙有关物质的方法 |
CN109020902B (zh) * | 2018-07-23 | 2020-06-02 | 唯智医药科技(北京)有限公司 | 一种瑞舒伐他汀钙杂质及其制备方法与用途 |
CN114280181A (zh) * | 2021-12-23 | 2022-04-05 | 浙江海翔川南药业有限公司 | 一种瑞舒伐他汀中间体及其有关物质的检测方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260440A (en) * | 1991-07-01 | 1993-11-09 | Shionogi Seiyaku Kabushiki Kaisha | Pyrimidine derivatives |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US37314A (en) * | 1863-01-06 | Improved composition for lemonade | ||
US633198A (en) * | 1899-02-08 | 1899-09-19 | Wilhelm Magnus Hoekerstedt | Automatic-lighting torch. |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US4739073A (en) | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
ES2110499T3 (es) | 1991-06-19 | 1998-02-16 | Shionogi & Co | Intermediario opticamente activo y su produccion. |
GB9626746D0 (en) | 1996-12-23 | 1997-02-12 | Knoll Ag | Process |
GB9812413D0 (en) | 1998-06-10 | 1998-08-05 | Glaxo Group Ltd | Compound and its use |
SI20070A (sl) | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nove soli inhibitorjev HMG-CoA reduktaze |
GB9903472D0 (en) | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
US6777552B2 (en) | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
GB0028429D0 (en) | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
WO2003016317A1 (en) | 2001-08-16 | 2003-02-27 | Teva Pharmaceutical Industries Ltd. | Processes for preparing calcium salt forms of statins |
SE0103509D0 (sv) | 2001-10-19 | 2001-10-19 | Astrazeneca Ab | Rosuvastatin in pre demented states |
KR100511533B1 (ko) | 2002-04-09 | 2005-08-31 | 임광민 | 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법 |
BR0311195A (pt) | 2002-05-21 | 2005-02-22 | Ranbaxy Lab Ltd | Processo de preparação de rosuvastatina |
GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
WO2004052867A1 (en) | 2002-12-10 | 2004-06-24 | Ranbaxy Laboratories Limited | Process for the preparation of rosuvastatin |
AU2003269478A1 (en) | 2003-08-27 | 2005-03-16 | Hetero Drugs Limited | A novel process for amorphous rosuvastatin calcium |
US20070191318A1 (en) * | 2003-10-22 | 2007-08-16 | Yatendra Kumar | Process for the preparation of amorphous rosuvastatin calcium |
CA2546701C (en) | 2003-11-24 | 2010-07-27 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
WO2005056534A1 (en) * | 2003-12-02 | 2005-06-23 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
WO2006035277A2 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium |
WO2006079611A1 (en) | 2005-01-31 | 2006-08-03 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of rosuvastatin calcium salt |
US20090124803A1 (en) | 2005-03-22 | 2009-05-14 | Pandurang Balwant Deshpande | Process for preparation of rosuvastatin |
WO2006106526A1 (en) | 2005-04-04 | 2006-10-12 | Unichem Laboratories Limited | Process for preparation of calcium salt of rosuvastatin |
CA2611920C (en) | 2005-06-24 | 2015-05-05 | Lek Pharmaceuticals D.D. | Process for preparing pure amorphous rosuvastatin calcium |
EP1912952B1 (en) | 2005-06-24 | 2014-10-15 | LEK Pharmaceuticals d.d. | Process for preparing amorphous rosuvastatin calcium free of impurities |
GB0514078D0 (en) | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
-
2004
- 2004-12-02 WO PCT/US2004/040329 patent/WO2005056534A1/en active Application Filing
- 2004-12-02 JP JP2006541502A patent/JP4733047B2/ja not_active Expired - Fee Related
- 2004-12-02 CN CN2004800359220A patent/CN1894221B/zh not_active Expired - Fee Related
- 2004-12-02 TW TW093137210A patent/TWI351958B/zh not_active IP Right Cessation
- 2004-12-02 PT PT04812772T patent/PT1689723E/pt unknown
- 2004-12-02 US US11/001,912 patent/US7244844B2/en active Active
- 2004-12-02 CA CA002546894A patent/CA2546894C/en not_active Expired - Fee Related
- 2004-12-02 KR KR1020067013302A patent/KR100887264B1/ko active IP Right Grant
- 2004-12-02 AT AT04812772T patent/ATE507209T1/de not_active IP Right Cessation
- 2004-12-02 ES ES04812772T patent/ES2364143T3/es active Active
- 2004-12-02 EP EP04812772A patent/EP1689723B1/en not_active Revoked
- 2004-12-02 DE DE602004032465T patent/DE602004032465D1/de active Active
-
2006
- 2006-05-09 IL IL175511A patent/IL175511A/en active IP Right Grant
-
2007
- 2007-06-25 US US11/821,968 patent/US7692008B2/en not_active Expired - Fee Related
- 2007-06-25 US US11/823,019 patent/US7692009B2/en not_active Expired - Fee Related
- 2007-06-25 US US11/823,013 patent/US7741482B2/en not_active Expired - Fee Related
- 2007-06-25 US US11/823,045 patent/US7692010B2/en not_active Expired - Fee Related
-
2009
- 2009-01-27 US US12/322,042 patent/US8487097B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260440A (en) * | 1991-07-01 | 1993-11-09 | Shionogi Seiyaku Kabushiki Kaisha | Pyrimidine derivatives |
Also Published As
Publication number | Publication date |
---|---|
ES2364143T3 (es) | 2011-08-25 |
DE602004032465D1 (de) | 2011-06-09 |
US20070249831A1 (en) | 2007-10-25 |
US7692009B2 (en) | 2010-04-06 |
US20070255059A1 (en) | 2007-11-01 |
JP2007512354A (ja) | 2007-05-17 |
US20050187234A1 (en) | 2005-08-25 |
KR100887264B1 (ko) | 2009-03-06 |
CA2546894A1 (en) | 2005-06-23 |
US20090188305A1 (en) | 2009-07-30 |
EP1689723B1 (en) | 2011-04-27 |
CA2546894C (en) | 2009-09-08 |
TWI351958B (en) | 2011-11-11 |
US7244844B2 (en) | 2007-07-17 |
IL175511A0 (en) | 2006-09-05 |
ATE507209T1 (de) | 2011-05-15 |
PT1689723E (pt) | 2011-07-06 |
US20070249830A1 (en) | 2007-10-25 |
US7692010B2 (en) | 2010-04-06 |
CN1894221B (zh) | 2012-08-08 |
US20070244321A1 (en) | 2007-10-18 |
US7692008B2 (en) | 2010-04-06 |
IL175511A (en) | 2011-11-30 |
US7741482B2 (en) | 2010-06-22 |
EP1689723A1 (en) | 2006-08-16 |
KR20060098396A (ko) | 2006-09-18 |
WO2005056534A1 (en) | 2005-06-23 |
CN1894221A (zh) | 2007-01-10 |
TW200522959A (en) | 2005-07-16 |
US8487097B2 (en) | 2013-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7692010B2 (en) | Reference standard for characterization of rosuvastatin | |
JP4996786B2 (ja) | 結晶質の化合物ビス[(e)−7−[4−(4−フルオロフェニル)−6−イソプロピル−2−[メチル(メチルスルホニル)アミノ]ピリミジン−5−イル](3r,5s)−3,5−ジヒドロキシ−6−ヘプテン酸]カルシウム塩 | |
JPH02250870A (ja) | コレステロール生合成抑制性化合物 | |
JPH0641448B2 (ja) | 3−デメチルメバロン酸誘導体 | |
JP2007512357A (ja) | 不純物を実質的に含まないアトルバスタチンカルシウムの形態を調製するための方法 | |
JP5330225B2 (ja) | トリオール型ロスバスタチン | |
US7884226B2 (en) | Purification of rosuvatatin intermediate by thin film evaporation and chemical method | |
WO2009090158A1 (en) | Atorvastatin-aliskiren | |
EP2334667A1 (en) | A process for preparation of rosuvastatin acetonide calcium | |
Schneider et al. | Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection | |
CN101631777A (zh) | 罗苏伐他汀的三醇形式 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071002 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080829 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20080902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100406 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100705 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100812 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101019 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110119 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110202 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110322 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110421 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140428 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4733047 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |